Relationships between survival and expressions of estrogen receptor α and β in non-smoking nonsmall cell lung cancer patients

简红; 朱雷; 邵晋辰; 赵艺; 李传佳; 虞永锋; 张杰

doi:10.3969/j.issn.1007-3969.2013.11.010

您当前的位置：

首页 >

文章列表页 >

Relationships between survival and expressions of estrogen receptor α and β in non-smoking nonsmall cell lung cancer patients

更新时间：2025-12-31

- Relationships between survival and expressions of estrogen receptor α and β in non-smoking nonsmall cell lung cancer patients
- China Oncology Vol. 23, Issue 11, Pages: 910-916(2013)
- 作者机构：
  
  1. 上海交通大学附属上海市胸科医院肺部肿瘤临床医学中心,上海,200030
  2. 上海交通大学附属上海市胸科医院病理科,上海,200030
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2013.11.010
  CLC：
- Published Online：18 February 2014，
  
  Published：18 February 2013
- 稿件说明：
移动端阅览
简红,朱雷,邵晋辰,赵艺,李传佳,虞永锋,张杰. ERα、ERβ在非吸烟非小细胞肺癌患者中的表达与生存期和性别的相关性研究[J]. 中国癌症杂志, 2013, 23(11): 910-916.

简红, 朱雷, 邵晋辰, et al. Relationships between survival and expressions of estrogen receptor α and β in non-smoking nonsmall cell lung cancer patients[J]. China Oncology, 2013, 23(11): 910-916.
简红,朱雷,邵晋辰,赵艺,李传佳,虞永锋,张杰. ERα、ERβ在非吸烟非小细胞肺癌患者中的表达与生存期和性别的相关性研究[J]. 中国癌症杂志, 2013, 23(11): 910-916. DOI： 10.3969/j.issn.1007-3969.2013.11.010.

简红, 朱雷, 邵晋辰, et al. Relationships between survival and expressions of estrogen receptor α and β in non-smoking nonsmall cell lung cancer patients[J]. China Oncology, 2013, 23(11): 910-916. DOI： 10.3969/j.issn.1007-3969.2013.11.010.

摘要

背景与目的：雌激素信号传导在非小细胞肺癌(non-small cell lung cancer，NSCLC)中存在争议，体外实验发现，雌激素受体(estrogen receptor，ER)ERβ与肺内组织的异常增生相关，ERβ在正常组织和肺癌组织中的表达结果不同。本研究旨在探讨ERα和ERβ在非吸烟NSCLC患者中的表达与临床病理特征和生存期的关系。方法：收集有组织学病理诊断的144例非吸烟的NSCLC组织及其临床资料，免疫组化方法检测ERα和ERβ表达状况并分析与临床特点和生存期的关系。结果：ERα阳性表达率为7.6%，仅在腺癌中表达，ERα表达状态与生存期无关。ERβ表达率为52.1%，Ⅰ、Ⅱ期患者的表达显著高于Ⅲ、Ⅳ期，差异有统计学意义(P=0.020)。ERβ表达阳性和阴性的中位生存期(median survival time，MST)分别为43和38个月，差异有统计学意义(P=0.028)，ERβ表达阳性和阴性的女性MST分别为45和37个月，差异有统计学意义(P=0.033)。在腺癌中ERβ阳性和阴性表达的MST分别为46和38个月，差异有统计学意义(P=0.021)。结论：ERβ在早期非吸烟NSCLC中表达增高，是女性、腺癌生存期良好的标志。

Abstract

Background and purpose: The involvement of estrogen signaling in lung cancer is controversial. But the findings showed that ERβ might play an important role in neoplastic lung biology. Several studies have evaluated expression of ERβ in both normal and neoplastic human lung tissues with variable conclusions. We aimed to evaluate the expressive of estrogen receptors (ER) α

β in non-smoking non-small cell lung cancer (NSCLC) and investigate the relationships between the survival and expressions of ERα

β. Methods: Immunohistochemical assay was used to detect the expression ERα and ERβ in 144 NSCLC patients

and analyzed the expressions status of ERα

β and survival. Results: The positive rate of ERα was 7.6%

only in adenocarcinoma cancer. The positive rate of ERβwas 52.1%

and the expressions of stage Ⅰ and Ⅱ was significantly higher than that of stage Ⅲ and Ⅳ (P=0.020). The median survival time (MST) of ERβ positive expression was better than that of negative expression (43 months vs 38 months

P=0.028). The MST of ERβ positive expression of female patients was better than that of negative expression (45 months vs 37 months

P=0.033). The MST of ERβ positive expression of adenocarcinoma were 46 months and better than negative 38 months (P=0.021). Conclusion: The expression of ERβ was significantly higher in early-stage non- smoking NSCLC. It indicated that the positive expression of ERβ was related to the better MST

especially in female adenocarcinoma patients.

关键词

Keywords

references

Views

1811

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with non-small cell lung cancer in China

Research advances in estrogen receptor low positive early breast cancer

Expression correlation between Efp and Plk3 in estrogen receptor-positive breast cancer

The correlation of 18F-fluoroestradiol uptake in patients with breast cancer to in vitro immunohistochemical assay of ER status

Related Author

Jian MING

Yan JIN

Qiang ZHENG

Yong YUAN

Lingchuan GUO

Yuan LI

Yizi JIN

Mingxi LIN

Related Institution

Department of Pathology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Pathology, The First Affiliated Hospital of Soochow University

Department of Pathology, Shaanxi Provincial Cancer Hospital

School of Public Health, Fudan University

Department of Medical Oncology, Fudan University Shanghai Cancer Center; Phase Ⅰ Clinical Trial Center, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰